Name:

Reveliza®

Type of medical product:

Protein based

Novelty:

Biosimilar

Field:

Cardiovascular diseases

Indications for use:

Acute myocardial infarction

Status:

Phase III clinical studies

Recombinant tissue plasminogen activator. Application - diseases predisposing to clotting: myocardial infarction, artery embolism and thrombosis, ischemic stroke. For top performance the agent is to be injected within first 6 hours.